Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Historically, multinational drugmakers sourced clinical-stage oncology antibodies and antibody-drug conjugates from China. Recent multibillion-dollar transactions from Novartis, Merck, and Novo Nordisk signal a shift toward acquiring preclinical-stage assets across diverse disease areas and novel modalities—such as mRNA-encoded T-cell engagers and molecular glues—demonstrating increasing Western confidence in early-stage, potentially first-in-class Chinese discovery.
Related Insights
A notable trend is the licensing of advanced clinical assets from Chinese biotechs to major global pharmaceutical companies for ex-China rights. Deals like Roche licensing Medilink's Phase 3 ADC and AbbVie licensing Reamgen's Phase 2 bispecific antibody signal China's evolution from a market to a source of high-value, late-stage innovation.
AstraZeneca's two major partnerships with Chinese firms, Apple Zeta Pharma (CAR-T) and CSPC Pharmaceutical (obesity), signal a strategic pivot. The company is actively sourcing early-to-mid-stage assets from China for global development, treating the country as an innovation hub and validating the R&D capabilities of its biotech sector.
Western pharmaceutical companies are no longer seeking cheap 'me-too' assets in China. Instead, they are paying premium prices for genuinely innovative drugs, as evidenced by a 10x increase in deal size over five years and a surge in patent filings from the region.
The perception of China's biotech industry as purely 'copycat' is outdated. Chinese firms are now developing novel assets, like PD-1 VEGF bispecifics, that represent a level of investment risk that Western VCs and pharma might avoid, signaling a clear shift towards original, high-impact innovation.
China has developed a first-rate biotech effort, enabling U.S. firms to buy or license preclinical assets more efficiently than building them domestically. This creates an arbitrage opportunity, leveraging China's R&D capabilities while relying on U.S. expertise and capital for global commercialization.
A trio of significant deals in one week—Novo Nordisk, Merck, and Novartis all partnering with Chinese biotechs—underscores a major trend. Western pharmaceutical giants are now aggressively sourcing early-stage, preclinical assets from China to fuel their global R&D pipelines.
Beyond sheer scale, China's innovation leads in complex, next-generation drug modalities like ADCs and bispecifics. Chinese biotechs now account for roughly one-third of the global Phase 1 and 2 pipelines for these advanced therapies, indicating a shift from iteration on established targets to leadership in new technology platforms.
In a dramatic shift from manufacturing to innovation, Chinese biopharma's share of global out-licensing deals (valued over $50M) has exploded. It grew from just 5% five years ago to 30% last year, and has already hit 42% in the first half of the current year, attracting massive investment from Western giants.
In a major strategic shift, large pharmaceutical companies are increasingly sourcing their M&A pipeline from China. Chinese assets now account for 30-40% of Big Pharma's early-stage acquisitions, up from single digits just a few years ago, primarily because they are significantly cheaper than US or European equivalents.
The next decade in biotech will prioritize speed and cost, areas where Chinese companies excel. They rapidly and cheaply advance molecules to early clinical trials, attracting major pharma companies to acquire assets that they historically would have sourced from US biotechs. This is reshaping the global competitive landscape.
